Quest Diagnostics Price Target Cut to $58.00 (DGX)
Mizuho decreased their price objective on shares of Quest Diagnostics (NYSE:DGX) from $62.00 to $58.00 in a research note issued on Thursday, AnalystRatings.NET reports. The firm currently has a “neutral” rating on the stock. Mizuho’s target price would suggest a potential downside of 1.28% from the stock’s previous close.
Quest Diagnostics (NYSE:DGX) traded up 0.39% during mid-day trading on Thursday, hitting $58.98. 2,986,952 shares of the company’s stock traded hands. Quest Diagnostics has a one year low of $55.16 and a one year high of $63.40. The stock has a 50-day moving average of $60.91 and a 200-day moving average of $59.78. The company has a market cap of $8.958 billion and a price-to-earnings ratio of 17.93.
Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Thursday, October 17th. The company reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by $0.18. The company had revenue of $1.79 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the previous year, the company posted $1.18 earnings per share. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, analysts predict that Quest Diagnostics will post $4.23 earnings per share for the current fiscal year.
A number of other firms have also recently commented on DGX. Analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Quest Diagnostics in a research note to investors on Friday, October 11th. They now have a $60.00 price target on the stock, down previously from $64.00. Separately, analysts at Wells Fargo & Co. reiterated a “market perform” rating on shares of Quest Diagnostics in a research note to investors on Thursday, October 10th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Quest Diagnostics in a research note to investors on Tuesday, October 8th. They now have a $65.00 price target on the stock. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $61.06.
Quest Diagnostics Incorporated (NYSE:DGX)is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.